Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Mediwound ( (MDWD) ) has issued an announcement.
On May 15, 2025, MediWound Ltd. held its annual general meeting where shareholders approved several key proposals. These included the re-election of board members, the reappointment of Somekh Chaikin as the independent auditor, the renewal of the executive compensation policy, and the approval of a cash bonus for the CEO. The approvals reflect strong shareholder support and are expected to reinforce the company’s governance and operational strategies.
The most recent analyst rating on (MDWD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
Mediwound’s stock score is influenced by its financial struggles, including persistent losses and cash flow challenges, which are major concerns. While technical indicators show some positive momentum, and strategic partnerships and clinical progress offer future potential, the current valuation and financial health are significant risks. The stock’s potential is contingent on improved financial stability and successful product commercialization.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. operates in the biopharmaceutical industry, focusing on developing, manufacturing, and commercializing products for the treatment of severe burns and chronic wounds. The company is based in Yavne, Israel, and is known for its innovative enzymatic technology.
Average Trading Volume: 76,878
Technical Sentiment Signal: Buy
Current Market Cap: $215.3M
For a thorough assessment of MDWD stock, go to TipRanks’ Stock Analysis page.